Ifosfamide or dacarbazine

Phase 3Small molecule

Ifosfamide or dacarbazine is one of 6 small molecule programs targeting Soft-tissue Sarcomas. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Soft-Tissue SarcomasRecruiting

Soft-Tissue SarcomasPhase 3

Recruiting

Competition

Competitive Landscape

5 competitors in Soft-Tissue Sarcomas

#DrugCompanyPhaseTrials

Adriamycin

Pfizer

Phase 3

1 2

Votrient

Novartis

Phase 1

1 3

Yervoy

Bristol-Myers Squibb

Phase 1

1 4

Opdivo

Bristol-Myers Squibb

Phase 1

1 5

Yondelis

AApotex Inc.

Phase 1

1 6

Ifosfamide or dacarbazine

IInstitut Bergonié

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Soft-Tissue Sarcomas

NCT03805022

Clinical

Trials by Indication[1]

Soft-tissue Sarcomas1 trial

Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Recruiting·IInstitut Bergonié·Phase 3·NCT03805022·351 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ifosfamide or dacarbazine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ifosfamide or dacarbazine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ifosfamide or dacarbazine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Institut Bergonié company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: IInstitut Bergonié

Ifosfamide or dacarbazine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Soft-tissue Sarcomas1 trial

References

Drug Info

Quick Facts

Related News